TRIO Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-88481
Key Product Details
Species Reactivity
Validated:
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
0.5 mg/ml
Product Summary for TRIO Antibody
Immunogen
The immunogen is a synthetic peptide directed towards the C-terminal region of Human TRIO. Peptide sequence: PGFVLGHTSAVIVENPDGTLKKSTSWHTALRLRKKSEKKDKDGKREGKLE The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Scientific Data Images for TRIO Antibody
![Western Blot: TRIO Antibody [NBP2-88481]](https://resources.bio-techne.com/images/products/TRIO-Antibody-Western-Blot-NBP2-88481-img0001.jpg "Western Blot: TRIO Antibody [NBP2-88481]")
Western Blot: TRIO Antibody [NBP2-88481]
Western Blot: TRIO Antibody [NBP2-88481] - Host: Rabbit. Target Name: TRIO. Sample Type: 721_B Whole Cell lysates. Antibody Dilution: 1.0ug/mlTRIO is strongly supported by BioGPS gene expression data to be expressed in Human 721_B cellsApplications for TRIO Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: TRIO
Alternate Names
ARHGEF23, EC 2.7.11.1, FLJ42780, PTPRF-interacting protein, tgat, triple functional domain (PTPRF interacting), triple functional domain protein
Gene Symbol
TRIO
Additional TRIO Products
Product Specific Notices for TRIO Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...